There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GDF-15


Brief Information

Name:Growth/differentiation factor 15
Target Synonym:NSAID-regulated gene 1 protein,GDF15,Growth Differentiation Factor 15,Non-Steroidal Anti-Inflammatory Drug-Activated Gene-1,Placental Bone Morphogenetic Protein,NRG-1,PDF,Growth/Differentiation Factor 15,Macrophage Inhibitory Cytokine-1,PTGF-Beta,Placenta
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GD5-H5269 Human Human GDF-15 / MIC-1 Protein, Fc Tag
GD5-H5149 Human Human GDF-15 / MIC-1 Protein, His Tag

Part of Bioactivity data

Human GDF-15, His TagHuman GDF-15, His Tag (Cat. No. GD5-H5149) ELISA bioactivity

Immobilized Human GDF-15, His Tag (Cat. No. GD5-H5149) at 1 μg/mL (100 μL/well) can bind Human GFR alpha-like Fc Chimera Protein with a linear range of 0.8-25 ng/mL (QC tested).

Synonym Name



Growth Differentiation Factor 15 (GDF-15), also called Macrophage Inhibitory Cytokine 1 (MIC-1). Expression of MIC-1 mRNA in monocytoid cells is up-regulated by a variety of stimuli associated with activation, including interleukin 1β, tumor necrosis factor α (TNF-α), interleukin 2, and macrophage colony-stimulating factor but not interferon γ, or lipopolysaccharide (LPS). It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk. Increased GDF-15 levels are associated with cardiovascular diseases such as hypertrophy, heart failure, atherosclerosis, endothelial dysfunction, obesity, insulin resistance, diabetes, and chronic kidney diseases in diabetes. Increased GDF-15 level is linked with the progression and prognosis of the disease condition.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GDF15 agonist (Lilly) Phase 1 Clinical Eli Lilly And Company Diabetes Mellitus Details
JNJ-9090 JNJ-9090 Phase 1 Clinical Johnson & Johnson Diabetes Mellitus, Type 2; Obesity Details
NN-9215 Human-GDF15; MIC-1; NN-9215; LA-GDF15 Phase 1 Clinical Novo Nordisk A/S Obesity Details
CTL-002 CTL-002 Phase 1 Clinical CatalYm GmbH Solid tumours Details
NGM-120 NGM-120 Phase 2 Clinical Ngm Biopharmaceuticals Ovarian Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Melanoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.